Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Centessa Pharmaceuticals (CNTA) Capital Expenditures (2022 - 2025)

Centessa Pharmaceuticals (CNTA) has disclosed Capital Expenditures for 4 consecutive years, with $234000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Capital Expenditures rose 588.24% to $234000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $268000.0, a 332.26% increase, with the full-year FY2024 number at $34000.0, down 79.88% from a year prior.
  • Capital Expenditures was $234000.0 for Q3 2025 at Centessa Pharmaceuticals, up from $34000.0 in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $652000.0 in Q4 2022 to a low of $10000.0 in Q2 2023.
  • A 4-year average of $157400.0 and a median of $65500.0 in 2023 define the central range for Capital Expenditures.
  • Peak YoY movement for Capital Expenditures: plummeted 95.71% in 2023, then skyrocketed 588.24% in 2025.
  • Centessa Pharmaceuticals' Capital Expenditures stood at $652000.0 in 2022, then tumbled by 95.71% to $28000.0 in 2023, then rose by 21.43% to $34000.0 in 2024, then surged by 588.24% to $234000.0 in 2025.
  • Per Business Quant, the three most recent readings for CNTA's Capital Expenditures are $234000.0 (Q3 2025), $34000.0 (Q3 2024), and $28000.0 (Q4 2023).